ACRS

XNAS

Aclaris Therapeutics, Inc.

Mkt Cap $509MPHARMACEUTICAL PREPARATIONS

FUNDAMENTALS

P/S

82.63

EV/EBITDA

-8.49

P/B

4.81

EPS (TTM)

$-0.50

ROE

-48.5%

ROA

-35.1%

FCF

$-52.0M

MKT CAP

$691.3M

TECHNICAL ANALYSIS

Bullish

RSI-14

69.6

Neutral

MACD

0.280

Bullish

SMA-50

$4.01

SMA-200

$2.90

BOLL %B

0.95

Within bands

ATR-14

$0.26

RVOL

1.45x

Normal

MOMENTUM

+5.8%

10d +13.1% / 30d +34.8%

Analysis History

AI PREDICTION

No prediction yet

Tap Analyze to generate

REVENUE & GROWTH

$2M

Revenue

+54.1%

QoQ

+37.2%

YoY

Gross Margin

80.2%Expanding

ANALYST CONSENSUS

88% Buy

14 Buy2 Hold0 Sell

Low

Mean

High

$17

SHORT & FLOAT

Free Float

81.6%

Short interest is high at 7.9M shares with 5.3 days to cover, and short volume is rising (57.8% of daily volume), indicating bearish positioning but also potential for a squeeze if buying pressure continues.

Latest Headlines

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

ca.finance.yahoo.com5/8/2026

Aclaris Therapeutics (NASDAQ: ACRS) deepens loss while boosting R&D

stocktitan.net5/6/2026

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

finance.yahoo.com5/6/2026